Jim Cramer’s Charitable Trust Plans to Trim Cardinal Health and Eli Lilly
Jim Cramer’s Charitable Trust plans to reduce its holdings in Cardinal Health (CAH) and Eli Lilly (LLY) after both stocks rose over 20% since late September. The trust will sell 50 CAH shares at ~$273 each and 10 LLY shares at ~$1,420 each, reducing their portfolio weightings. Both companies recently reported stronger-than-expected earnings and raised outlooks.
How this was made

The 30-second read
Why it matters
The fund’s trimming may cause short‑term price pressure but the continued ownership indicates no fundamental concern.
Market read
Fund rebalancing could nudge both stocks lower in the short term, but broader market impact is limited.
What to watch
Both companies recently posted strong earnings, which could offset the impact of the trust’s modest sell.
Background
Jim Cramer’s Charitable Trust is adjusting its health‑care exposure after recent strong price gains in Cardinal Health and Eli Lilly.
Ticker impact
Jim Cramer’s Charitable Trust announced it will sell 50 shares of Cardinal Health, reducing its weighting to 2.75%.
likely slight downward pressure as the fund reduces its stake
A known large investor is trimming its position; the market often reacts with modest price dips.
The trust plans to sell 10 shares of Eli Lilly, cutting its weighting to 2.6% while keeping a sizable holding.
likely slight downward pressure as the fund reduces exposure
Even a small sell from a high‑profile fund can influence short‑term sentiment.
Market effects
Health‑care sector may see modest headwinds as a prominent fund trims exposure.
U.S. equities could see slight softening in health‑care stocks.
Limited to U.S. health‑care equities; no broader global effect.
Counterpoint
The trust’s continued holding suggests confidence; the sell may be a tactical rebalancing rather than a negative signal.
Key entities
- InvestorJim Cramer’s Charitable Trust
A charitable trust managed by media personality Jim Cramer.
- CompanyCardinal Health
U.S. health‑care services and products provider.
- CompanyEli Lilly
Pharmaceutical company.



